Shots:
- Tempus AI has entered into a definitive agreement to acquire Personalis, expanding Tempus’ capabilities in minimal residual disease (MRD)
- As per the deal, Personalis shareholders will receive $16.25 per share, valuing the company at an enterprise value of $1.5B, net of Tempus AI’s existing ownership interest; closing expected in late 2026 or early 2027
- The transaction will be structured as a 100% stock deal, with Tempus having the option to elect cash for up to 50% of the consideration. Personalis shareholders will receive a floating exchange ratio of Tempus AI common stock, capped at 0.3356 shares per Personalis share, with the final ratio to be determined closer to closing
Ref: Businesswire | Image: Personalis | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
